BioCardia (BCDA) director Bill Facteau awarded 8,000 stock options at $1.20
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioCardia, Inc. director Bill Facteau received a grant of stock options representing the right to buy 8,000 shares of common stock. The options have an exercise price of $1.20 per share and expire on July 6, 2036.
All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. After this grant, his directly held option awards total 23,729 underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Facteau Bill
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 8,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 23,729 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 8,000 options
Exercise price: $1.20 per share
Expiration date: July 6, 2036
+2 more
5 metrics
Options granted
8,000 options
Grant for common stock on July 6, 2026
Exercise price
$1.20 per share
Exercise price of granted stock options
Expiration date
July 6, 2036
Option term end date
Post-grant option holdings
23,729 shares
Total underlying common shares following transaction
Vesting schedule
100% after one year
Vests on one-year anniversary of grant, service-based
Key Terms
Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "1.2000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares are subject to the option vesting and becoming exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
service provider financial
"subject to the Reporting Person continuing as a service provider"
FAQ
What insider transaction did BioCardia (BCDA) report for Bill Facteau?
BioCardia reported that director Bill Facteau received a grant of stock options for 8,000 underlying common shares. The options were granted at an exercise price of $1.20 per share and represent a compensation-related award, not an open-market stock purchase or sale.
What are the key terms of Bill Facteau’s new BioCardia (BCDA) stock options?
Bill Facteau’s newly granted options cover 8,000 common shares at a $1.20 exercise price and expire on July 6, 2036. These terms define how many shares he can buy, at what price, and the latest date he can exercise the options.
When do Bill Facteau’s BioCardia (BCDA) stock options vest?
All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant date. Vesting is contingent on Facteau continuing as a service provider to BioCardia through that anniversary, aligning the award with his ongoing service to the company.
Is Bill Facteau’s BioCardia (BCDA) Form 4 transaction a market buy or sell?
The Form 4 shows a grant or award acquisition of options, not a market buy or sell of common stock. The transaction is coded as an “A” for grant, with no open-market purchase or sale of BioCardia shares reported in this filing.